ZURA BIO LIMITED Earnings Per Share (Diluted)
ZURA BIO LIMITED (ZURA) reported Earnings Per Share (Diluted) of -$0.21 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- ZURA BIO LIMITED earnings per share, diluted for the quarter ending 2026-06-30 was -$0.21.
- ZURA BIO LIMITED earnings per share, diluted for the quarter ending 2026-03-31 was -$0.22.
- ZURA BIO LIMITED earnings per share, diluted for the quarter ending 2025-12-31 was -$0.18.
- ZURA BIO LIMITED earnings per share, diluted for the quarter ending 2025-09-30 was -$0.21.
- ZURA BIO LIMITED earnings per share, diluted for fiscal 2025 was -$1.06.
- ZURA BIO LIMITED earnings per share, diluted for fiscal 2024 was -$0.60.
- ZURA BIO LIMITED earnings per share, diluted for fiscal 2023 was -$2.09.
| Period end | Earnings Per Share, Diluted 2 month | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 5 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 8 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 11 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.21 10-Q · filed 2026-08-11 | -$0.42 10-Q · filed 2026-08-11 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2026-03-31 | -$0.22 10-Q · filed 2026-05-07 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.06 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$0.21 10-Q · filed 2025-11-13 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.57 10-Q · filed 2025-11-13 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-06-30 | -$0.17 10-Q · filed 2026-08-11 | -$0.36 10-Q · filed 2026-08-11 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-03-31 | -$0.19 10-Q · filed 2026-05-07 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||||
| 2024-12-31 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.60 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$0.26 10-Q · filed 2025-11-13 | -$0.38 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.52 10-Q · filed 2025-11-13 | -$0.74 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2024-06-30 | -$0.17 10-Q · filed 2025-08-14 | -$0.22 10-Q · filed 2025-08-14 | -$0.47 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$0.65 derived: net income ÷ weighted average shares · filed 2025-08-14 | ||||
| 2024-03-31 | -$0.02 10-Q · filed 2025-05-08 | -$0.35 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$0.52 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$1.34 derived: net income ÷ weighted average shares · filed 2025-05-08 | ||||
| 2023-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$0.36 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$1.19 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$2.09 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | -$0.18 10-Q · filed 2024-11-07 | -$1.04 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.22 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$1.31 10-Q · filed 2024-08-13 | -$2.88 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$2.76 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$141.97 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | -$2.87 10-Q · filed 2023-11-13 | -$8.44 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$57.14 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$9.54 10-Q · filed 2023-08-14 | -$162.30 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$72395.48 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |